Adient is developing a next-generation absorbable inferior vena cava (IVC) filter designed to provide protection against pulmonary embolisms.
Cordis-X is betting big on a next-generation technology that could provide protection against pulmonary embolisms (PE).
The Menlo Park, CA-based company reported an $11.5 million series F investment in Adient Medical, a company developing an absorbable inferior vena cava (IVC) filter. The device is designed to avoid risks of perforation, migration, fracture, and thrombosis currently associated with IVC filters. Such safety issues have been the focus of the FDA-mandated PRESERVE (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters) study of IVC filters from six manufacturers.
In 2012, Jeremy Durack, MD, chief clinical officer of Cordis-X, authored a seminal paper exposing the safety concerns with metal filters. He has since served as a member of Adient’s scientific advisory board and will now join Adient as the chief clinical officer. Durack will work collaboratively with Adient Chief Medical Officer Joseph Steele, MD, and Matthew Johnson, principal investigator of PRESERVE and of Adient’s upcoming pivotal study, on clinical validation of Adient’s technology.